Macrogenics Inc. | Ownership
Companies that own Macrogenics Inc.
OppenheimerFunds, Inc.
4,109,540
9.73%
160,170
0.05%
06/30/2018
Bellevue Asset Management AG
3,257,325
7.71%
93,762
1.03%
06/30/2018
Fidelity Management & Research Co.
3,041,194
7.2%
-369,841
0.01%
06/30/2018
BlackRock Fund Advisors
2,872,799
6.8%
436,938
0%
06/30/2018
T. Rowe Price Associates, Inc.
2,235,971
5.29%
-23,020
0.01%
06/30/2018
Tavistock Life Sciences Co. (Investment Management)
2,222,426
5.26%
-955,000
3.33%
06/30/2018
The Vanguard Group, Inc.
2,024,914
4.79%
378,655
0%
06/30/2018
SSgA Funds Management, Inc.
1,517,112
3.59%
476,510
0%
06/30/2018
Ecor1 Capital LLC
1,450,606
3.43%
0
3.3%
06/30/2018
Point72 Asset Management LP
1,084,417
2.57%
0
0.12%
06/30/2018
| Address |
9740 Medical Center Drive
Rockville Maryland 20850
United States
|
|
Employees
|
- |
| Website |
http://www.macrogenics.com |
| Updated |
07/08/2019 |
| MacroGenics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. Its portfolio includes Margetuximab, Flotetuzumab, MGA012, MGD013, Enoblituzumab, MGD009, and Teplizumab. The company was founded by Scott E. |
